Status:
COMPLETED
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hyperlipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Eligibility Criteria
Inclusion
- Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
- LDL-C \< 6.0 mmol/l
- Triglyceride level \< 5.0 mmol/l.
Exclusion
- Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
370 Patients enrolled
Trial Details
Trial ID
NCT00136942
Start Date
April 1 2005
Last Update
February 18 2021
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Binningen, Basel-Landschaft, Switzerland
2
Pfizer Investigational Site
Liestal, Basel-Landschaft, Switzerland
3
Pfizer Investigational Site
Basel, Canton of Basel-City, Switzerland
4
Pfizer Investigational Site
Langenthal, Canton of Bern, Switzerland